



**CELLERANT**  
THERAPEUTICS

**Contacts: Kari Lampka**  
**508-647-0209**  
**klampka@macbiocom.com**

**Heather Cox**  
**202-628-8778 x13**  
**heather@fiercemarkets.com**

**For Release June 21, 2005**

**FierceBiotech Honors Cellerant Therapeutics as One of the "Fierce 15" Biotech Companies of 2005**

**SAN CARLOS, CA – June 21, 2005** – Cellerant Therapeutics announced today that it has been named to FierceBiotech's annual Fierce 15 list. This distinction honors Cellerant as one of the top 15 emerging biotech companies for 2005. FierceBiotech, an internationally recognized email newsletter covering the biotechnology and pharmaceutical markets, evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position.

"Cellerant is in a race to create the first approved product from adult stem cells and they think they may be within 18 months of having their first product on the market. That's no easy task," said John Carroll, of FierceBiotech. "Like the other swiftly developing companies on this year's Fierce 15 list, we'll be watching Cellerant closely in the years ahead."

Cellerant is developing a portfolio of products focused on the regulation of the hematopoietic (blood-forming) system. Its first program involves the use of pure hematopoietic stem cells for the curative treatment of genetic blood disorders, autoimmune disease and cancer. The company intends to conduct trials in sickle cell disease and lupus in 2006. Cellerant's second program is a unique cell-based biologic, Myeloid Progenitors (MP), which is being developed for the treatment of cancer chemotherapy- and radiation-induced neutropenia, a life-threatening condition associated with severe damage to the blood-forming system. The MP program is also being supported by federal grants for the treatment of people exposed to radiation after a nuclear terror incident.

"FierceBiotech is recognized for its advanced understanding of biotechnology companies and the industry as a whole," said Bruce Cohen, President and CEO of Cellerant. "Being selected as a member of the Fierce 15 is an honor that highlights Cellerant's potential to make a significant impact in the biotech market."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. The list of Fierce 15 companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at <http://www.fiercebiotech.com>.

### **About FierceBiotech**

FierceBiotech, an internationally recognized email newsletter for the biotech industry, provides more than 35,000 executives a must-read briefing on the day's top stories in the biotech and pharmaceutical industries. Visit <http://www.fiercebiotech.com> for additional information.

### **About Cellerant**

Cellerant Therapeutics Inc. (<http://www.cellerant.com>) is a biotechnology company developing and commercializing the use of hematopoietic (blood-forming) stem cell-based products and therapies for the treatment of cancer, autoimmune disease, and genetic blood disorders. The company's extensive portfolio of intellectual property and clinical assets are licensed from Novartis and Stanford University. Cellerant has exclusive rights to the human highly purified hematopoietic stem cell population and process, the subject of several issued U.S. and foreign patents, and the human myeloid progenitor cell population and process, the subject of two issued U.S. patents and several pending U.S. and foreign patents.

###